VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

Importance of Molecular Classification

Insights From:F. Anthony Greco, MD, Sarah Cannon Cancer Center; Suresh S. Ramalingam, MD, Emory University
Published: Wednesday, Sep 30, 2015

 
Molecular classification of tumors with assays like CancerTYPE ID can be beneficial for determining the cancer type in patients with unclear or unknown primary cancers, says F. Anthony Greco, MD. Next-generation sequencing can then be performed using the same biopsy. This can help to guide targeted treatment, including in malignancies of the lung, colon, and breast. Understanding the cancer type and applying the appropriate treatment improves patient outcomes, states Greco.

If CancerTYPE ID results show that a patient has a high probability of having lung cancer, this information can help direct clinicians to look for abnormalities that are common in lung cancer, says Suresh S. Ramalingam, MD. Clinicians may then be able to identify actionable mutations in EGFR or ALK from molecular testing. Physicians should understand the importance of molecular testing in cancers, comments Ramalingam, which is particularly valuable during the time of diagnosis in advanced stage disease.
 
Slider Left
Slider Right

 
Molecular classification of tumors with assays like CancerTYPE ID can be beneficial for determining the cancer type in patients with unclear or unknown primary cancers, says F. Anthony Greco, MD. Next-generation sequencing can then be performed using the same biopsy. This can help to guide targeted treatment, including in malignancies of the lung, colon, and breast. Understanding the cancer type and applying the appropriate treatment improves patient outcomes, states Greco.

If CancerTYPE ID results show that a patient has a high probability of having lung cancer, this information can help direct clinicians to look for abnormalities that are common in lung cancer, says Suresh S. Ramalingam, MD. Clinicians may then be able to identify actionable mutations in EGFR or ALK from molecular testing. Physicians should understand the importance of molecular testing in cancers, comments Ramalingam, which is particularly valuable during the time of diagnosis in advanced stage disease.
 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x